utahvast.blogg.se - Keymo rhearpoy

#KEYMO RHEARPOY PLUS#

Some patients receiving HERCEPTIN for breast cancer had the following side effects: Side Effects Seen Most Often With HERCEPTIN Your doctor may check for signs of low white blood cell counts when he or she examines you.

#KEYMO RHEARPOY PLUS#

Low white blood cell counts were seen more often in patients receiving HERCEPTIN plus chemotherapy than in patients receiving chemotherapy alone. Low white blood cell counts can be life threatening. Your doctor may check for signs of severe lung problems when he or she examines you.

Weakening of the valve between the heart and the lungs.

Have any signs of SEVERE LUNG PROBLEMS, including:

If you are or become pregnant while receiving HERCEPTIN or within 7 months after your last dose of HERCEPTIN, you should immediately report HERCEPTIN exposure to Genentech at 1-88.

Contraception should be used while receiving HERCEPTIN and for 7 months after your last dose of HERCEPTIN. HERCEPTIN may result in the death of an unborn baby or birth defects. These signs usually happen within 24 hours after receiving HERCEPTIN.Īre a woman who could become pregnant, or may be pregnant Your doctor will check for signs of heart problems before, during, and after treatment with HERCEPTIN. In a study of adjuvant (early) breast cancer, one patient died of significantly weakened heart muscle. The risk for and seriousness of these heart problems were highest in people who received both HERCEPTIN and a certain type of chemotherapy (anthracycline). These include heart problems-such as congestive heart failure or reduced heart function-with or without symptoms. Be sure to contact your doctor if you are experiencing any of the following: Patients are selected for therapy based on an FDA-approved test for trastuzumab. HERCEPTIN HYLECTA alone is approved for the treatment of HER2-positive breast cancer in patients who have received one or more chemotherapy courses for metastatic disease.HERCEPTIN HYLECTA in combination with the chemotherapy drug paclitaxel is approved for the first line treatment of Human Epidermal growth factor Receptor 2-positive ( HER2+) metastatic breast cancer.HERCEPTIN HYLECTA has 2 approved uses in adults with metastatic breast cancer: *High risk is defined as ER/PR-positive with one of the following features: tumor size >2 cm, age 2 cm, age <35 years, or tumor grade 2 or 3. Patients are selected for therapy based on an FDA-approved test for Herceptin.

Alone after treatment with multiple other therapies, including an anthracycline (doxorubicin) based therapy (a type of chemotherapy).

With the chemotherapy drugs docetaxel and carboplatin.

This treatment course is known as “ AC➝TH”

As part of a treatment course including the chemotherapy drugs doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel.

If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor / progesterone receptor (ER/PR)-negative or have one high-risk feature.* Herceptin can be used in several different ways: Herceptin is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive ( HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. Herceptin: Indications Adjuvant Breast Cancer